Let's get personal: predicting thiopurine and fluoropyrimidine toxicity

Personalized Medicine
Adele CorriganA Marinaki

Abstract

The US FDA now recognizes the need to individualize treatment paradigms using biomarkers that predict response to therapy. In clinical practice the best example of this is TPMT testing, which is used to rationalize the starting dose of azathioprine and mercaptopurine. The more recent addition of drug metabolite monitoring means that thiopurine therapy can now be personalized to unprecedented levels. Of interest, parallels exist between TPMT deficiency as an explanation for thiopurine toxicity and DPD deficiency in fluoropyrimidine toxicity. For these drugs, variations in a single locus predict severe toxicity. However, while TPMT testing has translated into routine clinical practice, DPD testing has not. This article summarizes the recent research investigating interindividual differences in the metabolism of thiopurine and fluoropyrimidine drugs, and explores the attitudes which influence the uptake of pharmacogenetic testing.

References

Aug 1, 1989·Clinical Pharmacology and Therapeutics·L LennardR M Weinshilboum
Jul 25, 1985·The New England Journal of Medicine·M TuchmanB L Mirkin
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M SchneiderF Demard
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M C EtienneG Milano
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R A FlemingF Demard
Nov 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Meta-Analysis Group In CancerP Thirion
Dec 1, 1998·British Journal of Pharmacology·C Spire-Vayron de la MoureyreF Broly
Feb 23, 1999·British Journal of Cancer·G MilanoN Renée
Dec 2, 1999·Journal of the National Cancer Institute·M V RellingW E Evans
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W E EvansM V Relling
Nov 8, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Di PaoloM Del Tacca
Sep 25, 2002·Alimentary Pharmacology & Therapeutics·A AnsariJ Sanderson
Oct 18, 2002·Human Genetics·Satoshi SumiJohn A Duley
Nov 7, 2003·Current Gastroenterology Reports·Marla C Dubinsky
Feb 18, 2004·Clinica Chimica Acta; International Journal of Clinical Chemistry·Rebecca L RobertsMartin A Kennedy
Apr 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lori K MattisonRobert B Diasio
May 29, 2004·Therapeutic Drug Monitoring·Luc J J DerijksPiet M Hooymans
Jun 4, 2004·The New England Journal of Medicine·Thierry AndréUNKNOWN Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC)
Aug 10, 2004·Annals of Clinical Biochemistry·Jeremy SandersonJohn Duley
Aug 28, 2004·The American Journal of Gastroenterology·Benjamin A GoldenbergCharles N Bernstein
Nov 17, 2004·Scandinavian Journal of Gastroenterology·U HindorfK Schmiegelow
Mar 18, 2005·Alimentary Pharmacology & Therapeutics·T KitiyakaraA S McIntyre
Nov 25, 2005·Clinical Chemistry·Monica ArenasAnthony M Marinaki
Jan 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lori K MattisonRobert B Diasio
Feb 14, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Miles P SparrowStephen B Hanauer
Feb 27, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthias SchwabUNKNOWN German 5-FU Toxicity Study Group
May 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Erick GamelinMichele Boisdron-Celle
Jul 12, 2008·Alimentary Pharmacology & Therapeutics·A AnsariJ Sanderson
Jul 30, 2008·British Journal of Clinical Pharmacology·Ahmed F HawwaJames C McElnay

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva
H CorominasM Baiget
British Journal of Clinical Pharmacology
L Lennard
© 2022 Meta ULC. All rights reserved